Table 8 Recent phase II trials of single agents in previously treated bladder cancer

From: A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

Drug

Author (ref.)

No. of pts

Evaluable pts

CR

PR

%

Duration (months)

TTP (months)

OS (months)

Paclitaxel

Vaughn (2002)

31

31

—

3

10

 

2.2

7.2

 

Papamichael (1997)

14

14

 

1

7

7.4

  
 

Joly (2004)

45

37

—

2

5

3.0

  

Docetaxel

McCaffrey (1997)

30

30

—

4

13

4.0

 

9.0

Oxaliplatin

Moore (2003)

20

18

—

1

6

   

Lapatinib

Wulfing (2005)

59

59

—

2

3

   

Bortezomib

Sridhar (2005)

18

11

—

—

0

   

Pemetrexed

Sweeney (2003)

47

47

3

10

28

3.0

 

9.8

Back to article page